- The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) increased by over 14% during intraday trading today. This is why it happened.
The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) – a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein p53 – increased by over 14% during intraday trading today. Investors are responding positively to Aprea Therapeutics announcing that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on the company’s clinical trial evaluating the combination of its lead compound, eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies.
“We are pleased to have addressed the FDA’s concerns and receive clearance to proceed with future clinical study of eprenetapopt in non-Hodgkin’s lymphomas. We look forward to continued evaluation of eprenetapopt as a therapeutic option for these patients with unmet medical need.”
— Eyal Attar, M.D., Chief Medical Officer of Aprea Therapeutics
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.